Bal Pharma reported a net profit of ₹675.12 lakh for the financial year ended March 31, 2026, a decline of 13.4% compared to ₹779.95 lakh in the previous year. Revenue from operations for the year rose 2.7% to ₹31,079.70 lakh from ₹30,249.64 lakh in FY25. The board has recommended a dividend of ₹1.20 per equity share, subject to shareholder approval at the ensuing Annual General Meeting. The company published these audited standalone and consolidated financial results in the Financial Express (English) and Sanjayvani (Kannada) on May 29, 2026, complying with Regulation 47 of the SEBI (LODR) Regulations, 2015.

Board Meeting Decisions

The Board of Directors met on May 27, 2026, to approve the audited standalone and consolidated financial results. In addition to the financial results, the board approved the preferential issue of 10,00,000 warrants to promoters and decided to seek shareholder approval for this fund-raising exercise through a postal ballot. The board also approved the grant of 5,00,000 stock options to employees under the Bal Pharma Limited – Employee Stock Option Plan-2025. Mr. Shreepada ML was appointed as Company Secretary and Compliance Officer, replacing Mr. Abdul Basith who resigned effective May 11, 2026.

Financial Performance

For the quarter ended March 31, 2026, the company recorded a net profit of ₹370.02 lakh, a decrease from ₹560.69 lakh in the same period last year. Quarterly revenue stood at ₹8,391.76 lakh. Total comprehensive income for the year increased to ₹718.50 lakh from ₹775.63 lakh in the previous year.

Auditor and Compliance

Statutory auditors SSJNB & Co issued an audit report with an unmodified opinion on the standalone and consolidated financial results. The board appointed Murugesh & Co as Internal Auditors and G.N.V & Associates as Cost Auditors for FY 2025-26. The trading window for designated persons and employees, which was closed from April 1, 2026, will remain closed until 48 hours after the declaration of financial results.

Bal Pharma Limited has notified the stock exchanges of the resignation of Mr. Abdul Basith (Membership No. A70640) from the position of Company Secretary & Compliance Officer of the company, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The resignation takes effect from the close of business hours on Monday, May 11, 2026, and was formally accepted on the same date.

Resignation Details

Mr. Abdul Basith had submitted his resignation letter on March 2, 2026, citing his decision to pursue an alternate career opportunity outside the organisation. In accordance with the company's HR policy, he had requested to be relieved of his responsibilities effective 60 days from the date of the resignation letter. The company accepted the resignation on May 11, 2026, marking the conclusion of his tenure as Company Secretary, Compliance Officer, and Deputy Nodal Officer (IEPF) of Bal Pharma Limited.

The key details of the resignation, as disclosed under the SEBI Listing Regulations and SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015, are as follows:

Interim Communication Arrangements

Bal Pharma Limited has informed the exchanges that until a formal announcement is made regarding the appointment of a new Company Secretary & Compliance Officer, all communications relating to the company should be directed to secretarial@balpharma.com . The intimation was signed by Shailesh Siroya, Managing Director of Bal Pharma Limited, on May 12, 2026.

The company has also indicated that the necessary statutory filings, including the relevant forms with the Registrar of Companies under the Ministry of Corporate Affairs, will be completed to give effect to the resignation.